MedPath
TGA Approval

BIKTARVY bictegravir (as sodium) 50 mg, emtricitabine 200 mg, tenofovir alafenamide (as fumarate) 25 mg fixed-dose combination tablets bottle (291923)

291923

BIKTARVY bictegravir (as sodium) 50 mg, emtricitabine 200 mg, tenofovir alafenamide (as fumarate) 25 mg fixed-dose combination tablets bottle

Gilead Sciences Pty Ltd

July 12, 2018

Medicine

Medicine

Active

Registered

Product Information

Consumer Medicine Information

http://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&id=CP-2018-CMI-02085-1

Product Information

http://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&id=CP-2018-PI-02084-1

Active Ingredients

bictegravir sodium

emtricitabine

tenofovir alafenamide fumarate

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

BIKTARVY bictegravir (as sodium) 50 mg, emtricitabine 200 mg, tenofovir alafenamide (as fumarate) 25 mg fixed-dose combination tablets bottle (291923) - TGA 批准文号 | MedPath